UiPath (NYSE:PATH) Given New $27.00 Price Target at Evercore ISI

UiPath (NYSE:PATH) had its price target hoisted by Evercore ISI from $24.00 to $27.00 in a research report released on Thursday, Benzinga reports. Evercore ISI currently has an in-line rating on the healthcare company’s stock.

Several other equities analysts have also weighed in on the company. TD Cowen lifted their price target on UiPath from $25.00 to $28.00 and gave the company an outperform rating in a research note on Thursday. Morgan Stanley boosted their target price on UiPath from $17.00 to $25.00 and gave the stock an equal weight rating in a report on Thursday. Wells Fargo & Company upped their price objective on UiPath from $18.00 to $20.00 and gave the company an equal weight rating in a report on Friday, December 1st. Barclays boosted their target price on UiPath from $23.00 to $25.00 and gave the company an equal weight rating in a research report on Friday. Finally, Scotiabank assumed coverage on UiPath in a research report on Wednesday, February 21st. They set a sector perform rating on the stock. Nine equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, UiPath presently has an average rating of Hold and a consensus price target of $27.13.

UiPath Stock Up 1.4 %

Shares of UiPath stock traded up $0.32 during trading on Thursday, reaching $23.07. The company’s stock had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. The company has a market cap of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97. The company has a 50-day simple moving average of $23.52 and a two-hundred day simple moving average of $20.70. UiPath has a 1-year low of $12.38 and a 1-year high of $27.87.

Insider Buying and Selling at UiPath

In other news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $22.47, for a total transaction of $359,520.00. Following the completion of the transaction, the chief financial officer now directly owns 103,505 shares of the company’s stock, valued at approximately $2,325,757.35. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Rich Wong sold 200,000 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now owns 429,418 shares in the company, valued at $9,928,144.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $22.47, for a total transaction of $359,520.00. Following the sale, the chief financial officer now owns 103,505 shares in the company, valued at approximately $2,325,757.35. The disclosure for this sale can be found here. Over the last three months, insiders sold 411,000 shares of company stock valued at $9,418,670. Corporate insiders own 31.03% of the company’s stock.

Institutional Trading of UiPath

Hedge funds have recently bought and sold shares of the company. Norges Bank purchased a new stake in UiPath during the 4th quarter worth $165,749,000. BlackRock Inc. boosted its stake in UiPath by 32.1% during the 2nd quarter. BlackRock Inc. now owns 23,376,854 shares of the healthcare company’s stock valued at $387,354,000 after purchasing an additional 5,681,577 shares during the period. Altimeter Capital Management LP boosted its stake in UiPath by 175.4% during the 1st quarter. Altimeter Capital Management LP now owns 8,275,000 shares of the healthcare company’s stock valued at $71,579,000 after purchasing an additional 5,270,194 shares during the period. Senvest Management LLC boosted its stake in UiPath by 188.4% during the 2nd quarter. Senvest Management LLC now owns 6,027,933 shares of the healthcare company’s stock valued at $99,883,000 after purchasing an additional 3,937,951 shares during the period. Finally, Millennium Management LLC boosted its stake in UiPath by 899.5% during the 4th quarter. Millennium Management LLC now owns 4,049,999 shares of the healthcare company’s stock valued at $51,475,000 after purchasing an additional 3,644,799 shares during the period. Institutional investors and hedge funds own 59.04% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.